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Background
HIV-1 diversity presents a challenge for the development
of an effective HIV vaccine. Cameroon in central Africa,
exhibits very broad HIV-1 genetic diversity. That makes it
one of the few places in the world where vaccine efficacy
can be tested against a broad range of subtypes and
recombinants. The aim of the study is to assess cross-clade
T cell responses in HIV-infected Cameroonians.
Methods
PBMCs were obtained from 36 HIV-1 infected blood
donors. T cell responses were determined using the IFNγ
ELISPOT assay using cryopreserved PBMC. Cells were
stimulated with overlapping peptide pools derived from
HIV-1 group M consensus Gag and Nef proteins. The first
line assay used a pool-matrix screening approach, and this
was followed by a confirmatory assay to identify single
reactive peptides.
Results
Thirty-six samples were tested in the IFNγ ELISPOT assay;
32 (89%) responded to at least 1 peptide pool. The
median magnitude response was 1995 spot forming units
(SFU)/106 PBMC among the responders (range 130 to
12853). At the protein level the median response to Gag
was 1083 SFU/106 PBMC, while the median response to
Nef was 1070 SFU/106 PBMC. The median number of
peptides recognized per individual was 5 (range 1 to 16)
with no difference in number of peptides recognized in
Gag and Nef (p = 0.1793). Most of the reactive peptides
targeted the conserved regions both in Gag and Nef. The
magnitude of the total response correlated inversely with
CD4 count (r = -0.4026 p = 0.0165), but no relationship
with viral load was evident. At the protein level, there was
no relationship between the Gag or Nef response and
CD4 count or viral load.
Conclusion
These data show that high magnitude T cell responses are
detectable in HIV-1 infected Cameroonians using Group
M peptide reagents, which likely reflects the broad HIV-1
genetic diversity in the population.
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